Search clinical trials for: Minimal Residual Disease monitoring

Total 386028 results

Goethe University
University Hospital Schleswig-Holstein

Recruiting

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

ALL, Recurrent, Adult

Germany
Hospital General de Mexico

Recruiting

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Acute Lymphoblastic Leukemia, in Relapse | Chemotherapeutic Toxicity | Minimal Residual Disease

Mexico
M.D. Anderson Cancer Center

Recruiting

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Myeloma Multiple

United States
Peking University People's Hospital
Guangzhou Burning Rock Medical Examination Institute Co., Ltd.; Beijing CSCO-Allist... and other collaborators

Not yet recruiting

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Adenocarcinoma of Lung

China
M.D. Anderson Cancer Center

Recruiting

DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease

Colorectal Cancer | Colon Cancer

United States
University of Alabama at Birmingham

Recruiting

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Multiple Myeloma

United States
Guangdong Provincial People's Hospital

Recruiting

MRD Monitoring in Lung Cancer After Resection

Lung Cancer

China
University of British Columbia
AstraZeneca; Ozmosis Research Inc.

Recruiting

SCION: SABR and Checkpoint Inhibition Of NSCLC (SCION)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Lung Cancer Stage I | Lung Adenocarcinoma, Stage I | Lung Squamous Cell Carcinoma Stage I

Canada
Meir Medical Center
Assuta Ashdod Hospital; Rabin Medical Center; Tel-Aviv Sourasky Medical Center; Ziv Medical Center

Recruiting

Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status (FLMRD)

Follicular Lymphoma

Israel
University of California, Irvine
Natera, Inc.; Taiho Pharmaceutical Co., Ltd.

Recruiting

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Colorectal Cancer | Colon Adenocarcinoma

United States
Roswell Park Cancer Institute
GlaxoSmithKline

Recruiting

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Plasma Cell Myeloma

United States
Helsinki University Central Hospital

Recruiting

Systemic Neoadjuvant and Adjuvant Control by Precision Medicine in Rectal Cancer (SYNCOPE)

Colorectal Cancer

Finland
Abramson Cancer Center at Penn Medicine
Johns Hopkins University; Pfizer; Translational Breast Cancer Research Consortium and other collaborators

Recruiting

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY)

Breast Cancer

United States
Stanford University

Recruiting

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer

United States
Paolo Ghia

Recruiting

Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) (VALUABLE)

Chronic Lymphocytic Leukemia (CLL)

Italy
M.D. Anderson Cancer Center

Recruiting

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

Colorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditions

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO) (HTLP-ONCO)

Hematologic Malignancy

France
University Hospital, Lille
Saint-Louis Hospital, Paris, France; Canceropôle Nord Ouest

Recruiting

Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia (FERTILAM)

Acute Myeloid Leukemia

France
Nanfang Hospital of Southern Medical University

Recruiting

CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia Not Having Achieved Remission

China
Seoul National University Hospital
Amgen

Recruiting

Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)

Minimal Residual Disease | Pediatric ALL, B Cell

Korea, Republic of
Abramson Cancer Center at Penn Medicine

Recruiting

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer (ABBY)

Breast Cancer

United States
Munich Leukemia Laboratory

Recruiting

Better Leukemia Diagnostics Through AI (BELUGA) (BELUGA)

Lymphoma | Leukemia | Hematologic Malignancy | Minimal Residual Disease | Blood Cancer

Germany
Memorial Sloan Kettering Cancer Center
Adaptive Biotechnologies

Recruiting

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Zhongda Hospital

Recruiting

Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

BCR-ABL1 Fusion Protein Expression | Acute Lymphocytic Leukemia, Adult B-Cell

China
Celularity Incorporated

Recruiting

Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01)

Neoplasms | Neoplasms by Histologic Type | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | Hematologic Neoplasms | Physiological Effects of Drugs | Peripheral Nervous System Agents | Analgesics | Analgesics, Non-narcotic | Antimetabolites, Antineoplastic | Leukemia in Remission | Relapsed... and other conditions

United States
Reade Rheumatology Research Institute
ZonMw: The Netherlands Organisation for Health Research and Development; Sint...

Recruiting

Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring (ADDORA)

Rheumatoid Arthritis

Netherlands
PETHEMA Foundation

Recruiting

Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

Acute Lymphoblastic Leukemia

Spain
Xianmin Song, MD

Recruiting

Next Generation Sequencing（NGS）Monitors Minimal Residual Disease（MRD）in Allo-PBSCT Patients

NGS Monitor MRD

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Hematologic and Lymphocytic Disorder | Acute Myeloid Leukemia in Remission | FLT3 Gene Mutation | Minimal Residual Disease Persistence

United States
Roswell Park Cancer Institute

Recruiting

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Colorectal Cancer | Metastatic Unresectable Sarcoma | Metastatic Malignant Neoplasm in the Lung | Resectable Sarcoma | Metastatic Soft Tissue Sarcoma | Metastatic Bone Sarcoma

United States
Novartis Pharmaceuticals
Children's Oncology Group

Recruiting

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA)

B-Cell Acute Lymphoblastic Leukemia

United States, Netherlands, Italy, Germany, Belgium, Canada, France, Spain, United Kingdom, Finland, Denmark, Sweden, Norway
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Elevated CA15-3 or CEA or CA27-29

United States, Puerto Rico, Guam
Polish Myeloma Consortium
Janssen-Cilag Ltd.; Bioscience, S.A.

Recruiting

Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma (PREDATOR)

Multiple Myeloma

Poland
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Minimal Residual Disease | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Minimal Residual Disease | Hematopoietic Cell Transplantation Recipient | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Recurrent B Acute Lymphoblastic Leukemia

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Mantle Cell Lymphoma | CD20 Positive

United States
Crystal Mackall, MD

Recruiting

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Refractory Acute Lymphoblastic Leukemia | Minimal Residual Disease | CD19 Positive

United States
University of Birmingham
Assistance Publique - Hôpitaux de Paris; Pfizer; Cancer Research UK; National Cancer...

Recruiting

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

Acute Myeloid Leukaemia

France, Switzerland, United Kingdom, New Zealand, Australia, Ireland
Lund University
South Sweden Breast Cancer Group; Mrs. Berta Kamprad Foundation; U-CAN

Recruiting

Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer (SCAN-B)

Breast Neoplasms

Sweden
Janssen Research & Development, LLC

Active, not recruiting

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA)

Multiple Myeloma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Hairy Cell Leukemia

United States
Noah Merin
Teva Branded Pharmaceutical Products R&D, Inc.; Miltenyi Biomedicine GmbH

Active, not recruiting

Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | CLL

United States
M.D. Anderson Cancer Center

Active, not recruiting

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Colon Cancer | Resected Stage

United States
Roswell Park Cancer Institute

Active, not recruiting

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Myeloproliferative Neoplasm | Minimal Residual Disease | Graft Versus Host Disease | Severe Aplastic Anemia | Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia... and other conditions

United States
Weill Medical College of Cornell University
AstraZeneca; Celgene Corporation

Active, not recruiting

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
Taiho

Suspended

TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Colorectal Cancer

United States
University of Cambridge
The Leeds Teaching Hospitals NHS Trust; Cambridge University Hospitals NHS... and other collaborators

Active, not recruiting

Closed Loop From Onset in Type 1 Diabetes (CLOuD)

Diabetes Mellitus | Type 1 Diabetes

United Kingdom
Washington University School of Medicine
National Cancer Institute (NCI); Invivoscribe, Inc.; T-Cell Leukemia Lymphoma...

Completed

Minimal Residual Disease in Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma

United States
University of Surabaya
Anesthesiology and Intensive Therapy, Faculty of Medicine, Universitas Gadjah...

Enrolling by invitation

Ability to Maintain Saturation Levels Without Oxygen Supplementation as a Extubation Criteria Without TOF Monitoring Equipment

Anesthesia Intubation Complication

Indonesia

Search clinical trials for: Minimal Residual Disease monitoring

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations